- Ono Pharma’s third-quarter operating income hit 14.87 billion yen, marking a 69% decrease year-over-year and falling short of the 19.01 billion yen estimate.
- The company’s net income in the third quarter was 14.95 billion yen, down by 59% year-over-year but slightly above the estimate of 14.76 billion yen.
- Net sales for the third quarter increased by 2.3% year-over-year to 134.22 billion yen, exceeding the estimate of 129.48 billion yen.
- For the nine-month period, operating income was down 51% year-over-year at 70.75 billion yen.
- Net income over the nine months also saw a decrease of 49% year-over-year, amounting to 56.59 billion yen.
- Net sales during the same period decreased by 3.9% year-over-year, totaling 374.56 billion yen.
- Research and development expenses surged by 40% year-over-year, reaching 107.07 billion yen.
- Ono Pharma maintains its full-year forecast for operating income at 82.00 billion yen, which is below the market estimate of 93.11 billion yen.
- The company continues to project net income of 58.00 billion yen for the year, short of the 63.95 billion yen estimate.
- Forecasted full-year net sales stand at 485.00 billion yen, slightly lower than the estimate of 489.17 billion yen.
- The dividend prediction remains consistent with estimates at 80.00 yen.
- Current market analysis shows 2 buy recommendations, 6 holds, and 6 sells for Ono Pharma shares.
“`
Ono Pharmaceutical on Smartkarma
Analysts on Smartkarma are closely following the developments at Ono Pharmaceutical, as highlighted in a recent report by Tina Banerjee. In her bearish analysis titled “Ono Pharmaceutical (4528 JP): Struggle Continues with Opdivo; Competition and Price Cuts Loom Large,” Banerjee notes that the company’s revenue from its flagship drug, Opdivo, is experiencing a slowdown. With the patent cliff looming in 2028, Ono Pharmaceutical faces challenges with limited growth prospects ahead. Reflecting these concerns, shares of Ono have declined by 36% over the past year.
Banerjee emphasizes the importance of Ono successfully commercializing new drugs to navigate the patent cliff effectively. Despite the current attractive valuation of Ono shares following the decline, the analyst sees a lack of near-term growth catalysts, suggesting limited upside potential in the absence of significant positive developments. This analysis underscores the cautious sentiment surrounding Ono Pharmaceutical‘s future prospects among independent analysts on Smartkarma.
A look at Ono Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Ono Pharmaceutical has been assigned impressive Smart Scores, indicating a positive long-term outlook for the company. With a strong score of 5 for Dividend and a solid score of 4 for Value, Ono Pharmaceutical is showing promise in providing returns to its investors while also being considered a valuable investment. Additionally, the company has received scores of 3 for Growth and Resilience, reflecting a moderate level of potential growth and stability in the face of challenges. Although the Momentum score is lower at 2, Ono Pharmaceutical‘s overall outlook appears promising.
ONO PHARMACEUTICAL CO., LTD. specializes in manufacturing and selling pharmaceuticals, with a primary focus on researching and developing prescription drugs. This core business activity positions Ono Pharmaceutical as a key player in the pharmaceutical industry, showcasing its commitment to innovation and healthcare advancement.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
